Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report sent to investors on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

BLPH opened at $0.04 on Friday. The company has a market capitalization of $452,510.00, a price-to-earnings ratio of -0.04 and a beta of 0.71. Bellerophon Therapeutics has a 12-month low of $0.03 and a 12-month high of $0.10. The business’s fifty day simple moving average is $0.04 and its 200-day simple moving average is $0.05.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.